1. Home
  2. Solutions
  3. Consulting
  4. Externalised development

Externalised development services

Redefining drug development partnership

Pharma and biotech sponsors often need a partner that can streamline strategy, reduce friction and maintain asset knowledge throughout the development lifecycle. 

ICON’s externalised development model unifies nonclinical expertise, strategic consultancy and clinical delivery within a flexible framework adapted to each sponsor’s resourcing needs.

End-to-end capabilities

Nonclinical strategy and oversight

Senior toxicology, pharmacology and DMPK experts support candidate selection, IND strategy, CRO oversight, regulatory documentation and early de‑risking across all major therapeutic areas and advanced modalities.

Read more
SVG Image
thumbnail

Drug development consultancy

More than 50 senior specialists provide translational planning, regulatory strategy, clinical development design and evidence strategy to help sponsors navigate key inflection points and optimise programme decisions.

Learn more
SVG Image
pills on manufactoring lane

Clinical operations and delivery

Integrated operational leadership delivers Phase 1-3 studies with connected data management, biostatistics, medical oversight and decentralised solutions, maintaining strategic alignment from early development to pivotal trials.

Explore
SVG Image
landing page

Commercial and market access alignment

Payer‑centred evidence planning, RWE and health economics expertise ensure programmes anticipate commercial requirements and support long‑term value.

Read more
SVG Image
Technology for real-world evidence

A partner that is an extension of your team

ICON operates a modular approach that can fully externalise development or integrate seamlessly alongside your teams. Standardised governance, secure data architecture and an asset‑centric mindset preserve institutional knowledge and ensure programme continuity.

Demonstrated impact

  • Integrated scientific, operational and regulatory expertise across the full development continuum
  • Asset‑centred approach that reduces internal burden and enhances decision quality
  • Proven track record in accelerating timelines and improving value outcomes
In this section

Connect with us